Literature DB >> 27344947

Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.

Rui Lu1, Ping Wang2, Trevor Parton3, Yang Zhou4, Kaliopi Chrysovergis5, Shira Rockowitz6, Wei-Yi Chen7, Omar Abdel-Wahab8, Paul A Wade5, Deyou Zheng9, Gang Greg Wang10.   

Abstract

DNA methyltransferase 3A (DNMT3A) is frequently mutated in hematological cancers; however, the underlying oncogenic mechanism remains elusive. Here, we report that the DNMT3A mutational hotspot at Arg882 (DNMT3A(R882H)) cooperates with NRAS mutation to transform hematopoietic stem/progenitor cells and induce acute leukemia development. Mechanistically, DNMT3A(R882H) directly binds to and potentiates transactivation of stemness genes critical for leukemogenicity including Meis1, Mn1, and Hoxa gene cluster. DNMT3A(R882H) induces focal epigenetic alterations, including CpG hypomethylation and concurrent gain of active histone modifications, at cis-regulatory elements such as enhancers to facilitate gene transcription. CRISPR/Cas9-mediated ablation of a putative Meis1 enhancer carrying DNMT3A(R882H)-induced DNA hypomethylation impairs Meis1 expression. Importantly, DNMT3A(R882H)-induced gene-expression programs can be repressed through Dot1l inhibition, providing an attractive therapeutic strategy for DNMT3A-mutated leukemias.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27344947      PMCID: PMC4945461          DOI: 10.1016/j.ccell.2016.05.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  45 in total

1.  Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia.

Authors:  Alan H Shih; Yanwen Jiang; Cem Meydan; Kaitlyn Shank; Suveg Pandey; Laura Barreyro; Ileana Antony-Debre; Agnes Viale; Nicholas Socci; Yongming Sun; Alexander Robertson; Magali Cavatore; Elisa de Stanchina; Todd Hricik; Franck Rapaport; Brittany Woods; Chen Wei; Megan Hatlen; Muhamed Baljevic; Stephen D Nimer; Martin Tallman; Elisabeth Paietta; Luisa Cimmino; Iannis Aifantis; Ulrich Steidl; Chris Mason; Ari Melnick; Ross L Levine
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

2.  The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.

Authors:  David A Russler-Germain; David H Spencer; Margaret A Young; Tamara L Lamprecht; Christopher A Miller; Robert Fulton; Matthew R Meyer; Petra Erdmann-Gilmore; R Reid Townsend; Richard K Wilson; Timothy J Ley
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

Review 3.  The role of mutations in epigenetic regulators in myeloid malignancies.

Authors:  Alan H Shih; Omar Abdel-Wahab; Jay P Patel; Ross L Levine
Journal:  Nat Rev Cancer       Date:  2012-08-17       Impact factor: 60.716

4.  Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.

Authors:  Y-I Chang; X You; G Kong; E A Ranheim; J Wang; J Du; Y Liu; Y Zhou; M-J Ryu; J Zhang
Journal:  Leukemia       Date:  2015-03-24       Impact factor: 11.528

5.  Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation.

Authors:  Allison Mayle; Liubin Yang; Benjamin Rodriguez; Ting Zhou; Edmund Chang; Choladda V Curry; Grant A Challen; Wei Li; David Wheeler; Vivienne I Rebel; Margaret A Goodell
Journal:  Blood       Date:  2015-01-22       Impact factor: 22.113

6.  AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation.

Authors:  Yuanyuan Li; Hong Wen; Yuanxin Xi; Kaori Tanaka; Haibo Wang; Danni Peng; Yongfeng Ren; Qihuang Jin; Sharon Y R Dent; Wei Li; Haitao Li; Xiaobing Shi
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

7.  DNMT3A mutations in acute myeloid leukemia.

Authors:  Timothy J Ley; Li Ding; Matthew J Walter; Michael D McLellan; Tamara Lamprecht; David E Larson; Cyriac Kandoth; Jacqueline E Payton; Jack Baty; John Welch; Christopher C Harris; Cheryl F Lichti; R Reid Townsend; Robert S Fulton; David J Dooling; Daniel C Koboldt; Heather Schmidt; Qunyuan Zhang; John R Osborne; Ling Lin; Michelle O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Vincent J Magrini; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Joshua J Conyers; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd Wylie; Jason Walker; Joelle Kalicki; Mark A Watson; Sharon Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Peter Westervelt; Michael H Tomasson; Daniel C Link; Timothy A Graubert; John F DiPersio; Elaine R Mardis; Richard K Wilson
Journal:  N Engl J Med       Date:  2010-11-10       Impact factor: 91.245

8.  Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

Authors:  Andrei V Krivtsov; David Twomey; Zhaohui Feng; Matthew C Stubbs; Yingzi Wang; Joerg Faber; Jason E Levine; Jing Wang; William C Hahn; D Gary Gilliland; Todd R Golub; Scott A Armstrong
Journal:  Nature       Date:  2006-07-16       Impact factor: 49.962

9.  NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis.

Authors:  Gang G Wang; Ling Cai; Martina P Pasillas; Mark P Kamps
Journal:  Nat Cell Biol       Date:  2007-06-24       Impact factor: 28.824

10.  Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger.

Authors:  Gang G Wang; Jikui Song; Zhanxin Wang; Holger L Dormann; Fabio Casadio; Haitao Li; Jun-Li Luo; Dinshaw J Patel; C David Allis
Journal:  Nature       Date:  2009-06-11       Impact factor: 49.962

View more
  71 in total

1.  Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7.

Authors:  Kelsey N Lamb; Daniel Bsteh; Sarah N Dishman; Hagar F Moussa; Huitao Fan; Jacob I Stuckey; Jacqueline L Norris; Stephanie H Cholensky; Dongxu Li; Jingkui Wang; Cari Sagum; Benjamin Z Stanton; Mark T Bedford; Kenneth H Pearce; Terry P Kenakin; Dmitri B Kireev; Gang Greg Wang; Lindsey I James; Oliver Bell; Stephen V Frye
Journal:  Cell Chem Biol       Date:  2019-08-15       Impact factor: 8.116

2.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation.

Authors:  Wenbin Xiao; Maheetha Bharadwaj; Max Levine; Noushin Farnhoud; Friederike Pastore; Bartlomiej M Getta; Anne Hultquist; Christopher Famulare; Juan S Medina; Minal A Patel; Qi Gao; Natasha Lewis; Janine Pichardo; Jeeyeon Baik; Brian Shaffer; Sergio Giralt; Raajit Rampal; Sean Devlin; Robert Cimera; Yanming Zhang; Maria E Arcila; Elli Papaemmanuil; Ross L Levine; Mikhail Roshal
Journal:  Blood Adv       Date:  2018-12-11

3.  Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.

Authors:  Wenyue Sun; Bishwanath Chatterjee; Jack F Shern; Rajesh Patidar; Young Song; Yonghong Wang; Robert L Walker; Bruce R Pawel; Corinne M Linardic; Peter Houghton; Stephen M Hewitt; Daniel C Edelman; Javed Khan; Paul S Meltzer; Frederic G Barr
Journal:  Int J Cancer       Date:  2019-01-15       Impact factor: 7.396

4.  Comparative Gene Expression Analyses Reveal Distinct Molecular Signatures between Differentially Reprogrammed Cardiomyocytes.

Authors:  Yang Zhou; Li Wang; Ziqing Liu; Sahar Alimohamadi; Chaoying Yin; Jiandong Liu; Li Qian
Journal:  Cell Rep       Date:  2017-09-26       Impact factor: 9.423

5.  BCR/ABL can promote CD19+ cell growth but not render them long-term stemness.

Authors:  Donghe Li; Xuemei Zhao; Ruihong Zhang; Bo Jiao; Ping Liu; Ruibao Ren
Journal:  Stem Cell Investig       Date:  2016-11-30

6.  E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia.

Authors:  Wen-Chieh Pi; Jun Wang; Miho Shimada; Jia-Wei Lin; Huimin Geng; Yu-Ling Lee; Rui Lu; Dongxu Li; Gang Greg Wang; Robert G Roeder; Wei-Yi Chen
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 7.  Marked for death: targeting epigenetic changes in cancer.

Authors:  Sophia Xiao Pfister; Alan Ashworth
Journal:  Nat Rev Drug Discov       Date:  2017-03-10       Impact factor: 84.694

8.  Abnormal RNA splicing and genomic instability after induction of DNMT3A mutations by CRISPR/Cas9 gene editing.

Authors:  Lauren G Banaszak; Valentina Giudice; Xin Zhao; Zhijie Wu; Shouguo Gao; Kohei Hosokawa; Keyvan Keyvanfar; Danielle M Townsley; Fernanda Gutierrez-Rodrigues; Maria Del Pilar Fernandez Ibanez; Sachiko Kajigaya; Neal S Young
Journal:  Blood Cells Mol Dis       Date:  2018-01-04       Impact factor: 3.039

Review 9.  Epigenetic plasticity and the hallmarks of cancer.

Authors:  William A Flavahan; Elizabeth Gaskell; Bradley E Bernstein
Journal:  Science       Date:  2017-07-21       Impact factor: 47.728

10.  ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.

Authors:  Ling Cai; Yi-Hsuan Tsai; Ping Wang; Jun Wang; Dongxu Li; Huitao Fan; Yilin Zhao; Rohan Bareja; Rui Lu; Elizabeth M Wilson; Andrea Sboner; Young E Whang; Deyou Zheng; Joel S Parker; H Shelton Earp; Gang Greg Wang
Journal:  Mol Cell       Date:  2018-09-27       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.